- Home
- JGH vs AVIR Comparison
JGH vs AVIR Comparison
Compare JGH & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- AVIR
- Stock Information
- Founded
- JGH 2014
- AVIR 2012
- Country
- JGH United States
- AVIR United States
- Employees
- JGH N/A
- AVIR N/A
- Industry
- JGH Investment Managers
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- JGH Finance
- AVIR Health Care
- Exchange
- JGH Nasdaq
- AVIR Nasdaq
- Market Cap
- JGH 296.7M
- AVIR 273.7M
- IPO Year
- JGH N/A
- AVIR 2020
- Fundamental
- Price
- JGH $11.90
- AVIR $2.87
- Analyst Decision
- JGH
- AVIR Hold
- Analyst Count
- JGH 0
- AVIR 1
- Target Price
- JGH N/A
- AVIR $6.00
- AVG Volume (30 Days)
- JGH 73.9K
- AVIR 382.7K
- Earning Date
- JGH 01-01-0001
- AVIR 05-13-2025
- Dividend Yield
- JGH 9.85%
- AVIR N/A
- EPS Growth
- JGH N/A
- AVIR N/A
- EPS
- JGH N/A
- AVIR N/A
- Revenue
- JGH N/A
- AVIR N/A
- Revenue This Year
- JGH N/A
- AVIR N/A
- Revenue Next Year
- JGH N/A
- AVIR N/A
- P/E Ratio
- JGH N/A
- AVIR N/A
- Revenue Growth
- JGH N/A
- AVIR N/A
- 52 Week Low
- JGH $10.36
- AVIR $2.60
- 52 Week High
- JGH $12.85
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- JGH 40.11
- AVIR 47.41
- Support Level
- JGH $11.75
- AVIR $2.77
- Resistance Level
- JGH $11.95
- AVIR $3.17
- Average True Range (ATR)
- JGH 0.40
- AVIR 0.22
- MACD
- JGH 0.01
- AVIR 0.02
- Stochastic Oscillator
- JGH 55.42
- AVIR 47.37
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).